Harmonising clinical trials within the Gynecologic Cancer InterGroup: Consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference

on behalf of the participants of the 5th Ovarian Cancer Consensus Conference

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The Gynecologic Cancer InterGroup (GCIG) Fifth Ovarian Cancer Consensus Conference (OCCC) was held in Tokyo, Japan from 7 to 9 November 2015. It provided international consensus on 15 important questions in 4 topic areas, which were generated in accordance with the mission statement to establish 'International Consensus for Designing Better Clinical Trials'. The methodology for obtaining consensus was previously established and followed during the Fifth OCCC. All 29 clinical trial groups of GCIG participated in program development and deliberations. Draft consensus statements were discussed in topic groups as well as in a plenary forum. The final statements were then presented to all 29 member groups for voting and documentation of the level of consensus. Full consensus was obtained for 11 of the 15 statements with 28/29 groups agreeing to 3 statements, and 27/29 groups agreeing to 1 statement. The high acceptance rate of the statements among trial groups reflects the fact that we share common questions, and recognise important unmet needs that will guide future research in ovarian cancer.

Original languageEnglish
Pages (from-to)viii30-viii35
JournalAnnals of Oncology
Volume28
DOIs
Publication statusPublished - 2017 Nov 1
Externally publishedYes

Fingerprint

Ovarian Neoplasms
Clinical Trials
Neoplasms
Program Development
Tokyo
Politics
Documentation
Japan

Keywords

  • Clinical trial
  • Consensus statement
  • Ovarian cancer

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Harmonising clinical trials within the Gynecologic Cancer InterGroup : Consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference. / on behalf of the participants of the 5th Ovarian Cancer Consensus Conference.

In: Annals of Oncology, Vol. 28, 01.11.2017, p. viii30-viii35.

Research output: Contribution to journalArticle

on behalf of the participants of the 5th Ovarian Cancer Consensus Conference. / Harmonising clinical trials within the Gynecologic Cancer InterGroup : Consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference. In: Annals of Oncology. 2017 ; Vol. 28. pp. viii30-viii35.
@article{95b4ad28ca6842cfaad190332372cad1,
title = "Harmonising clinical trials within the Gynecologic Cancer InterGroup: Consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference",
abstract = "The Gynecologic Cancer InterGroup (GCIG) Fifth Ovarian Cancer Consensus Conference (OCCC) was held in Tokyo, Japan from 7 to 9 November 2015. It provided international consensus on 15 important questions in 4 topic areas, which were generated in accordance with the mission statement to establish 'International Consensus for Designing Better Clinical Trials'. The methodology for obtaining consensus was previously established and followed during the Fifth OCCC. All 29 clinical trial groups of GCIG participated in program development and deliberations. Draft consensus statements were discussed in topic groups as well as in a plenary forum. The final statements were then presented to all 29 member groups for voting and documentation of the level of consensus. Full consensus was obtained for 11 of the 15 statements with 28/29 groups agreeing to 3 statements, and 27/29 groups agreeing to 1 statement. The high acceptance rate of the statements among trial groups reflects the fact that we share common questions, and recognise important unmet needs that will guide future research in ovarian cancer.",
keywords = "Clinical trial, Consensus statement, Ovarian cancer",
author = "{on behalf of the participants of the 5th Ovarian Cancer Consensus Conference} and Bookman, {M. A.} and A. Okamoto and G. Stuart and N. Yanaihara and Daisuke Aoki and M. Bacon and K. Fujiwara and A. Gonz{\'a}lez-Mart{\'i}n and P. Harter and Kim, {J. W.} and J. Ledermann and E. Pujade-Lauraine and M. Quinn and K. Ochiai and A. Zeimet and C. Marth and {du Bois}, A. and F. Hilpert and J. Pfisterer and A. Reuss and M. Friedlander and Wilson, {M. K.} and F. Kridelka and I. Vergote and J. Berek and O. Dorigo and A. Karam and Bekkers, {R. L.M.} and A. Westermann and C. Gatsonis and C. Ng and Herr{\'a}ez, {A. Casado} and N. Ottevanger and A. Poveda and A. Redondo and R. Coleman and K. Lu and D. Gallardo-Rinc{\'o}n and E. Gomez-Garcia and F. Joly and A. Leary and I. Ray-Coquard and R. Burger and Moore, {K. N.} and H. Fujiwara and K. Hasegawa and N. Gleeson and T. Levy and O. Rosengarten and N. Katsumata",
year = "2017",
month = "11",
day = "1",
doi = "10.1093/annonc/mdx449",
language = "English",
volume = "28",
pages = "viii30--viii35",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",

}

TY - JOUR

T1 - Harmonising clinical trials within the Gynecologic Cancer InterGroup

T2 - Consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference

AU - on behalf of the participants of the 5th Ovarian Cancer Consensus Conference

AU - Bookman, M. A.

AU - Okamoto, A.

AU - Stuart, G.

AU - Yanaihara, N.

AU - Aoki, Daisuke

AU - Bacon, M.

AU - Fujiwara, K.

AU - González-Martín, A.

AU - Harter, P.

AU - Kim, J. W.

AU - Ledermann, J.

AU - Pujade-Lauraine, E.

AU - Quinn, M.

AU - Ochiai, K.

AU - Zeimet, A.

AU - Marth, C.

AU - du Bois, A.

AU - Hilpert, F.

AU - Pfisterer, J.

AU - Reuss, A.

AU - Friedlander, M.

AU - Wilson, M. K.

AU - Kridelka, F.

AU - Vergote, I.

AU - Berek, J.

AU - Dorigo, O.

AU - Karam, A.

AU - Bekkers, R. L.M.

AU - Westermann, A.

AU - Gatsonis, C.

AU - Ng, C.

AU - Herráez, A. Casado

AU - Ottevanger, N.

AU - Poveda, A.

AU - Redondo, A.

AU - Coleman, R.

AU - Lu, K.

AU - Gallardo-Rincón, D.

AU - Gomez-Garcia, E.

AU - Joly, F.

AU - Leary, A.

AU - Ray-Coquard, I.

AU - Burger, R.

AU - Moore, K. N.

AU - Fujiwara, H.

AU - Hasegawa, K.

AU - Gleeson, N.

AU - Levy, T.

AU - Rosengarten, O.

AU - Katsumata, N.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - The Gynecologic Cancer InterGroup (GCIG) Fifth Ovarian Cancer Consensus Conference (OCCC) was held in Tokyo, Japan from 7 to 9 November 2015. It provided international consensus on 15 important questions in 4 topic areas, which were generated in accordance with the mission statement to establish 'International Consensus for Designing Better Clinical Trials'. The methodology for obtaining consensus was previously established and followed during the Fifth OCCC. All 29 clinical trial groups of GCIG participated in program development and deliberations. Draft consensus statements were discussed in topic groups as well as in a plenary forum. The final statements were then presented to all 29 member groups for voting and documentation of the level of consensus. Full consensus was obtained for 11 of the 15 statements with 28/29 groups agreeing to 3 statements, and 27/29 groups agreeing to 1 statement. The high acceptance rate of the statements among trial groups reflects the fact that we share common questions, and recognise important unmet needs that will guide future research in ovarian cancer.

AB - The Gynecologic Cancer InterGroup (GCIG) Fifth Ovarian Cancer Consensus Conference (OCCC) was held in Tokyo, Japan from 7 to 9 November 2015. It provided international consensus on 15 important questions in 4 topic areas, which were generated in accordance with the mission statement to establish 'International Consensus for Designing Better Clinical Trials'. The methodology for obtaining consensus was previously established and followed during the Fifth OCCC. All 29 clinical trial groups of GCIG participated in program development and deliberations. Draft consensus statements were discussed in topic groups as well as in a plenary forum. The final statements were then presented to all 29 member groups for voting and documentation of the level of consensus. Full consensus was obtained for 11 of the 15 statements with 28/29 groups agreeing to 3 statements, and 27/29 groups agreeing to 1 statement. The high acceptance rate of the statements among trial groups reflects the fact that we share common questions, and recognise important unmet needs that will guide future research in ovarian cancer.

KW - Clinical trial

KW - Consensus statement

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=85039545602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039545602&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdx449

DO - 10.1093/annonc/mdx449

M3 - Article

C2 - 29232472

AN - SCOPUS:85039545602

VL - 28

SP - viii30-viii35

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

ER -